ALX Oncology (ALXO) Competitors $1.59 -0.10 (-5.92%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ALXO vs. CTNM, YMAB, NGNE, SLRN, ENGN, TRVI, TNGX, BTMD, VYGR, and ATYRShould you be buying ALX Oncology stock or one of its competitors? The main competitors of ALX Oncology include Contineum Therapeutics (CTNM), Y-mAbs Therapeutics (YMAB), Neurogene (NGNE), Acelyrin (SLRN), enGene (ENGN), Trevi Therapeutics (TRVI), Tango Therapeutics (TNGX), biote (BTMD), Voyager Therapeutics (VYGR), and Atyr PHARMA (ATYR). These companies are all part of the "pharmaceutical products" industry. ALX Oncology vs. Contineum Therapeutics Y-mAbs Therapeutics Neurogene Acelyrin enGene Trevi Therapeutics Tango Therapeutics biote Voyager Therapeutics Atyr PHARMA Contineum Therapeutics (NASDAQ:CTNM) and ALX Oncology (NASDAQ:ALXO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, media sentiment, analyst recommendations, risk and community ranking. Do analysts recommend CTNM or ALXO? Contineum Therapeutics currently has a consensus price target of $29.25, suggesting a potential upside of 129.05%. ALX Oncology has a consensus price target of $8.50, suggesting a potential upside of 434.59%. Given ALX Oncology's higher probable upside, analysts plainly believe ALX Oncology is more favorable than Contineum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Contineum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20ALX Oncology 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is CTNM or ALXO more profitable? Contineum Therapeutics' return on equity of -49.92% beat ALX Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Contineum TherapeuticsN/A -49.92% -20.52% ALX Oncology N/A -93.02%-70.67% Does the MarketBeat Community believe in CTNM or ALXO? ALX Oncology received 41 more outperform votes than Contineum Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Contineum Therapeutics an outperform vote while only 62.82% of users gave ALX Oncology an outperform vote. CompanyUnderperformOutperformContineum TherapeuticsOutperform Votes8100.00% Underperform VotesNo VotesALX OncologyOutperform Votes4962.82% Underperform Votes2937.18% Which has better valuation & earnings, CTNM or ALXO? Contineum Therapeutics has higher revenue and earnings than ALX Oncology. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioContineum Therapeutics$50M6.58$22.72MN/AN/AALX OncologyN/AN/A-$160.80M-$2.98-0.53 Does the media favor CTNM or ALXO? In the previous week, Contineum Therapeutics had 2 more articles in the media than ALX Oncology. MarketBeat recorded 5 mentions for Contineum Therapeutics and 3 mentions for ALX Oncology. ALX Oncology's average media sentiment score of 0.80 beat Contineum Therapeutics' score of 0.72 indicating that ALX Oncology is being referred to more favorably in the news media. Company Overall Sentiment Contineum Therapeutics Positive ALX Oncology Positive Do insiders and institutionals hold more shares of CTNM or ALXO? 98.0% of ALX Oncology shares are held by institutional investors. 33.4% of ALX Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryContineum Therapeutics beats ALX Oncology on 9 of the 14 factors compared between the two stocks. Get ALX Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for ALXO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALXO vs. The Competition Export to ExcelMetricALX OncologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$83.86M$6.54B$5.25B$8.80BDividend YieldN/A2.91%5.07%4.00%P/E Ratio-0.5310.2586.1216.98Price / SalesN/A176.191,077.10114.31Price / CashN/A57.6743.2137.77Price / Book0.424.885.044.89Net Income-$160.80M$154.38M$122.32M$228.40M7 Day Performance-14.52%-8.12%-4.65%-3.68%1 Month Performance9.66%-3.16%-0.99%0.03%1 Year Performance-88.91%-4.63%23.64%13.82% ALX Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALXOALX Oncology3.6651 of 5 stars$1.59-5.9%$8.50+434.6%-88.2%$83.86MN/A-0.5340Short Interest ↓CTNMContineum Therapeutics1.933 of 5 stars$14.25-1.9%$29.25+105.3%N/A$367.34M$50M0.0031Positive NewsYMABY-mAbs Therapeutics2.5954 of 5 stars$7.93-2.9%$20.89+163.4%-32.6%$355.18M$84.55M-14.69150Analyst ForecastNews CoverageNGNENeurogene3.2229 of 5 stars$23.20-0.1%$60.83+162.2%-37.5%$344.64M$925,000.000.0090SLRNAcelyrin2.4643 of 5 stars$3.43-10.2%$11.75+242.6%-69.5%$344.12MN/A-1.39135ENGNenGene2.3528 of 5 stars$7.61-4.6%$29.78+291.3%+2.7%$336.51MN/A0.0031Short Interest ↑TRVITrevi Therapeutics3.5639 of 5 stars$4.36-5.0%$9.31+113.6%+181.0%$335.14MN/A-9.9120Short Interest ↓TNGXTango Therapeutics3.0941 of 5 stars$3.07-2.5%$13.14+328.1%-73.9%$329.77M$43.38M-2.6090Positive NewsGap DownBTMDbiote2.858 of 5 stars$6.06-2.3%$9.11+50.3%+22.3%$329.28M$193.06M23.31194Positive NewsVYGRVoyager Therapeutics4.8524 of 5 stars$6.01-0.5%$17.43+190.0%-32.8%$328.30M$163.78M8.46100Analyst RevisionNews CoverageATYRAtyr PHARMA2.9761 of 5 stars$3.91-1.8%$19.25+392.3%N/A$328.21M$235,000.00-4.1656Short Interest ↑Analyst RevisionNews CoveragePositive News Related Companies and Tools Related Companies Contineum Therapeutics Competitors Y-mAbs Therapeutics Competitors Neurogene Competitors Acelyrin Competitors enGene Competitors Trevi Therapeutics Competitors Tango Therapeutics Competitors biote Competitors Voyager Therapeutics Competitors Atyr PHARMA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALXO) was last updated on 1/14/2025 by MarketBeat.com Staff From Our PartnersStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredThis Crypto Is Set to Explode in JanuaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALX Oncology Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ALX Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
